Global specialty pharmaceutical company Lotus Pharmaceutical (美時化學製藥; 1795 TT) announced that it has executed a definitive asset purchase agreement with OM Pharma, a global biopharmaceutical company headquartered in Geneva, Switzerland. Under the terms of the agreement, Lotus will acquire the South Korean market assets for OM Pharma's specialty biopharmaceutical product engineered for the prevention of recurrent urinary tract infections (UTIs). The transaction includes the formal transfer of drug licenses (marketing authorizations), registered trademarks, commercial finished goods inventory, and all associated intellectual property rights.

• Strategic Rationale: The transaction strengthens Lotus' specialty brands portfolio and expands its commercial footprint in South Korea, which remains one of its core profitable markets in the Asia-Pacific region.
• Asset Demographics & Market Base: The acquired biopharmaceutical asset features a mature clinical profile and long-standing market presence with high differentiation within its therapeutic category. Marketed across more than 40 countries, the product reached over one million patients globally in 2025. Within South Korea, the therapeutic maintains strong clinical adoption and high physician endorsement.
• Executive Commentary:
• Petar Vazharov, CEO of Lotus Pharmaceutical: "This acquisition in South Korea advances a deliberate corporate strategy to strengthen our localized market position. It reflects our commitment to building an optimized portfolio of differentiated brands that address unmet patient needs. Moving forward, we will continue to seek high-standard, value-creative, and socially impactful acquisition opportunities across Asia."
• Pascal Schumacher, Chief Commercial Officer of OM Pharma: "This transaction supports our ongoing efforts to maintain best-in-class access to preventive solutions for patients suffering from recurrent UTIs in South Korea, while enabling our organization to further fund our primary innovation and R&D pipelines."

Resource:美時收購韓國專科藥品 拓展泌尿科與感染疾病預防藥品組合